Abiraterone Acetate; Niraparib Tosylate Patent Expiration

1. Akeega patent expiration

AKEEGA's oppositions filed in EPO
AKEEGA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8436185 JANSSEN BIOTECH Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(4 years from now)

US8071623 JANSSEN BIOTECH Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(6 years from now)

US11673877 JANSSEN BIOTECH Niraparib compositions
Mar, 2038

(13 years from now)

US11091459 JANSSEN BIOTECH Niraparib compositions
Mar, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 JANSSEN BIOTECH DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8143241 JANSSEN BIOTECH DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US8859562 JANSSEN BIOTECH Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

US11207311 JANSSEN BIOTECH Method of treating prostate cancer
Jul, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET

More Information on Dosage

AKEEGA family patents

Family Patents